JP2008540552A - 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 - Google Patents

増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 Download PDF

Info

Publication number
JP2008540552A
JP2008540552A JP2008511301A JP2008511301A JP2008540552A JP 2008540552 A JP2008540552 A JP 2008540552A JP 2008511301 A JP2008511301 A JP 2008511301A JP 2008511301 A JP2008511301 A JP 2008511301A JP 2008540552 A JP2008540552 A JP 2008540552A
Authority
JP
Japan
Prior art keywords
adrenergic receptor
substance
receptor agonist
eye
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008511301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540552A5 (enExample
Inventor
パトリック・エム・ヒューズ
ジェイムズ・エイ・バーク
ジョーン−エン・チャン−リン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2008540552A publication Critical patent/JP2008540552A/ja
Publication of JP2008540552A5 publication Critical patent/JP2008540552A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2008511301A 2005-05-10 2006-05-09 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療 Pending JP2008540552A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67977105P 2005-05-10 2005-05-10
PCT/US2006/018019 WO2006122165A2 (en) 2005-05-10 2006-05-09 Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011209152A Division JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Publications (2)

Publication Number Publication Date
JP2008540552A true JP2008540552A (ja) 2008-11-20
JP2008540552A5 JP2008540552A5 (enExample) 2011-06-16

Family

ID=37397258

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008511301A Pending JP2008540552A (ja) 2005-05-10 2006-05-09 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2011209152A Pending JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2014156852A Pending JP2015013863A (ja) 2005-05-10 2014-07-31 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011209152A Pending JP2012046530A (ja) 2005-05-10 2011-09-26 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
JP2014156852A Pending JP2015013863A (ja) 2005-05-10 2014-07-31 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療

Country Status (8)

Country Link
US (3) US7931909B2 (enExample)
EP (2) EP1879553B1 (enExample)
JP (3) JP2008540552A (enExample)
AU (1) AU2006244083A1 (enExample)
BR (1) BRPI0608978A2 (enExample)
CA (1) CA2603069C (enExample)
ES (1) ES2798259T3 (enExample)
WO (1) WO2006122165A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534217A (ja) * 2018-08-21 2021-12-09 アラーガン、インコーポレイテッドAllergan, Incorporated 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CN106075449A (zh) 2005-07-14 2016-11-09 尼奥塞蒂克斯公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
JP5122460B2 (ja) * 2005-09-16 2013-01-16 アラーガン、インコーポレイテッド 治療薬の眼内輸送のための組成物および方法
US20070203144A1 (en) * 2006-01-17 2007-08-30 Allergan, Inc. Use of Memantine and Brimonidine to Attenuate Vitreoretinal Vascular Endothelial Growth Factor (VEGF) Protein Levels in Animals
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
EP2178502A2 (en) * 2007-06-21 2010-04-28 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010118340A1 (en) * 2009-04-09 2010-10-14 University Of Medicine And Dentistry Of New Jersey Treatment of cutaneous hemangioma
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
NZ716349A (en) 2009-11-09 2017-07-28 Allergan Inc Compositions and methods for stimulating hair growth
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
US8653123B2 (en) 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
BR112013012994A2 (pt) 2010-11-24 2016-09-13 Lithera Inc formulações monoterapêuticas de beta-agonista de longa duração, lipofílicas e seletivas e métodos para o tratamento cosmético da adiposidade e saliência de contorno
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
WO2012082633A1 (en) 2010-12-16 2012-06-21 Allergan, Inc. Novel 1,2- bis-sulfonamide derivatives as chemokine receptor modulators
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
CA2856507C (en) 2011-11-21 2017-03-21 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
US20130190324A1 (en) * 2011-12-23 2013-07-25 The Regents Of The University Of Colorado, A Body Corporate Topical ocular drug delivery
US20130197002A1 (en) 2012-01-30 2013-08-01 Allergan, Inc. Brimonidine for treating visual disorders mediated by central visual projections from the eye
ES2791534T3 (es) 2012-03-01 2020-11-04 Allergan Inc Derivados de benzofuran-2-sulfonamida como moduladores del receptor de quimiocinas
WO2014052518A1 (en) 2012-09-27 2014-04-03 Allergan, Inc. Biodegradable drug delivery systems for the sustained release of proteins
WO2014113384A2 (en) 2013-01-15 2014-07-24 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system drug delivery device
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
WO2014159657A1 (en) 2013-03-12 2014-10-02 Allergan, Inc. Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
JP2016513677A (ja) 2013-03-15 2016-05-16 アカディア ファーマシューティカルズ インコーポレイテッド ムスカリンアゴニスト
WO2015084869A1 (en) 2013-12-02 2015-06-11 Allergan, Inc. Benzothiophene sulfonamides derivatives as chemokine receptor modulators
KR101587483B1 (ko) * 2014-03-28 2016-01-21 동아대학교 산학협력단 미토콘드리아성 복합체 ⅰ 저해제를 유효성분으로 함유하는 증식성 유리체망막병증의 예방 또는 치료용 약학적 조성물
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
AU2016359288C1 (en) 2015-11-23 2022-03-17 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
WO2017201255A1 (en) 2016-05-20 2017-11-23 The Regents Of The University Of Colorado, A Body Corporate Lacrimal drug delivery device
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
EP3562489A4 (en) * 2016-12-27 2020-07-29 University of Utah Research Foundation INTRAOCULAR DRUG ADMINISTRATION DEVICE AND RELATED PROCESSES
CA3082643A1 (en) * 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CA3144406A1 (en) 2019-06-27 2020-12-30 Layerbio, Inc. Ocular device delivery methods and systems
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
WO2021216378A1 (en) 2020-04-23 2021-10-28 The Schepens Eye Research Institute, Inc. Methods and materials for treatment of fibrosis
US20230301993A1 (en) * 2020-08-21 2023-09-28 Vyluma Inc. Low-Dose Ophthalmic Compositions and Methods
EP4199905A4 (en) * 2020-08-21 2025-02-26 University of Tennessee Research Foundation Methods of neuroprotection and uses thereof
WO2022251710A2 (en) 2021-05-28 2022-12-01 Sight Sciences, Inc. Intraocular devices, systems, and methods
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534387A (ja) * 1999-01-04 2002-10-15 アラーガン・セイルズ・インコーポレイテッド 神経損傷の処置に（２−イミダゾリン−２−イルアミノ）キノキサリンを使用する方法
JP2007535552A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
EP1003569B1 (en) * 1997-08-11 2004-10-20 Allergan, Inc. Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20030114460A1 (en) * 2001-12-14 2003-06-19 Allergan Sales, Inc. Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
EP1487498B1 (en) 2002-03-18 2009-05-20 Novartis AG Topical composition comprising a cyclofructan, a carrier and a drug
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534387A (ja) * 1999-01-04 2002-10-15 アラーガン・セイルズ・インコーポレイテッド 神経損傷の処置に（２−イミダゾリン−２−イルアミノ）キノキサリンを使用する方法
JP2007535552A (ja) * 2004-04-30 2007-12-06 アラーガン、インコーポレイテッド α−２アドレナリン受容体アゴニストの眼内インプラントおよび視力の向上方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021534217A (ja) * 2018-08-21 2021-12-09 アラーガン、インコーポレイテッドAllergan, Incorporated 視力を改善するためのａ−２−アドレナリン受容体アゴニストの使用

Also Published As

Publication number Publication date
BRPI0608978A2 (pt) 2010-02-17
EP1879553A2 (en) 2008-01-23
EP3656374A1 (en) 2020-05-27
JP2015013863A (ja) 2015-01-22
US20080112923A1 (en) 2008-05-15
ES2798259T3 (es) 2020-12-10
CA2603069C (en) 2014-01-28
WO2006122165A3 (en) 2007-05-31
CA2603069A1 (en) 2006-11-16
US20080112922A1 (en) 2008-05-15
US7931909B2 (en) 2011-04-26
US20060257452A1 (en) 2006-11-16
WO2006122165A2 (en) 2006-11-16
AU2006244083A1 (en) 2006-11-16
JP2012046530A (ja) 2012-03-08
EP1879553B1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
JP2015013863A (ja) 増大した前眼部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
US20230285279A1 (en) Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
US8609144B2 (en) Sustained release intraocular implants and methods for preventing retinal dysfunction
JP5485314B2 (ja) ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント
JP5985536B2 (ja) 生分解性眼内インプラント
JP2013126997A (ja) β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラント
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
JP2007535564A (ja) 抗興奮毒性剤持続放出眼内インプラントおよび関連方法
AU2012202755A1 (en) Ocular therapy using alpha-2 adrenergic receptor agonists having enhanced anterior clearance rates

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110328

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110404

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110426

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110426

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524